For our tenth episode, we're exploring a company that operates at the beautiful intersection of two unstoppable forces: an aging global population and the relentless march of technology. This is a company that helps people walk again after a fall... helps surgeons operate with robotic precision... and even saves lives in the critical moments of a stroke. We are talking about a quiet giant in the world of medical technology... Stryker Corporation.

One of the most powerful and undeniable trends in the world is the aging of the global population. This creates a massive, long-term tailwind for companies that provide essential medical care, and few are better positioned than Stryker ($SYK). As a leader in medical technology, Stryker's products are critical in operating rooms and hospitals everywhere, from hip and knee replacements powered by its Mako robotic arm to neurovascular devices that treat strokes.


But the MedTech industry is intensely competitive, with constant pressure on pricing from hospitals and insurance companies. With a stock that often reflects its high-quality reputation through a premium valuation, investors need to ask: Can Stryker's innovation and market leadership continue to justify the price and fend off giants like Johnson & Johnson and Medtronic? We're putting Stryker's business under the surgical microscope to see if this healthcare leader is a healthy addition to a long-term portfolio.


Created with love by Emil Lazzaroni 
2 new episodes per week, until I can find good companies to hold forever. 

This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content. 

Always consult a professional before investing.